InsiderTrades

Form 4/A for SOPH SOPHiA GENETICS SA

Accepted 2026-04-08 08:47:32 ET · period of report 2026-04-02 · accession 0001840706-26-000110 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DA 2026-04-08 08:47 2026-04-02 SOPH Van Well Daan CLO A - Grant $0.00 +97.5K 358.8K +37% $0
DA 2026-04-08 08:47 2026-04-02 SOPH Van Well Daan CLO A - Grant $0.00 +142.2K 142.2K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2026-04-02 A A 97,536 $0.00 358,774 D — — (F1) Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030. (F2) This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 97,536 ordinary shares due to an inadvertent error. The correct amount is 358,774 ordinary shares.
2 Derivative Share Option (Right to Buy) 2026-04-02 A A 142,216 $0.00 142,216 D $5.04 · — to 2036-04-02 142,216 Ordinary Shares (F3) The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.